Clinical Trial Update: HuMax-CD20 in Active Rheumatoid Arthritis, Phase I/II [Phase 2]

View source ↗

Summary

A Phase II trial of HuMax-CD20 for active rheumatoid arthritis has completed. The study was sponsored by GlaxoSmithKline.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• HuMax-CD20 (ofatumumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Arthritis, Rheumatoid | Phase 2 | Status: COMPLETED